Portage Biotech Inc Stock Price - PTGEF

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Ultimate Trader
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type
Portage Biotech Inc PTGEF OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.125 0.00 0.00 0.00 0.125 19:00:00
Bid Price Ask Price Spread Spread % News
0.10 0.12 0.02 16.67% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Portage Biotech Inc Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 136.18M 1.09B $ 123.74M - - 156.36M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
485.00 $ - 0.00% - -

more financials information »

Portage Biotech Inc News

Loading Messages....

Latest PTGEF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PTGEF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.070.1250.070.1254,6000.05578.57%
3 Months0.070.1250.070.10013310,3220.05578.57%
6 Months0.090.1250.070.092217587,0730.03538.89%
1 Year0.00010.1360.00010.0956903106,4050.1249124,900.0%
3 Years0.1275410.6550.00010.2461845290,438-0.00254-1.99%
5 Years0.110.6550.00010.2110345237,6990.01513.64%

Portage Biotech Inc Description

Portage is engaged in researching and developing pharmaceutical and biotech products through to clinical "proof of concept" with an initial focus on unmet clinical needs. Following proof of concept, Portage will look to sell or license the products to large pharmaceutical companies for further development and commercialization. Portage has two operating subsidiaries, portage Pharmaceuticals Limited ("PPL") which is wholly owned by Portage and Biohaven Pharmaceutical Holding Company Limited ("Biohaven") in which Portage holds 49.18% as at June 30, 2016. PPL has successfully validated CellPorter®, a novel and proprietary cell permeable peptide platform that has been shown to efficiently deliver active biologic agents into cells without disrupting the cell membrane. PPL will be advancing its lead candidate, PPL-003, to an Investigational New Drug (IND) application for the topical treatment of Dry Eye Disease and Uveitis. Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. The Company’s first drug candidate, BHV-0223, is a novel formulation of a glutamate-modulating agent, being developed under FDA 505(b)(2) guidelines. Biohaven’s second compound, BHV-4157, is an NCE for neurodegenerative and neuropsychiatric disorders.


Your Recent History
USOTC
PTGEF
Portage Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.